Drastic changes to Ampligen clinical trial hurts ME patients – sign the petition to fight it

Author:

Patients in the Ampligen clinical trial are bearing the brunt of drastic changes Hemispherx has implemented that will force many to stop getting this medicine and may endanger prospects for FDA approval.
We need the community’s help in telling Hemispherx to put patients first, so we can continue to fight for FDA approval of the first medicine for ME. Sign the petition.
Four changes made by the drug maker are forcing patients off the medicine and threaten the continuation of the clinical trial:

  1. A 167% price increase.
  2. Ending the compassionate care program, which supports less than a handful of patients who need the assistance.
  3. Restricting access to current full-time enrollees only, which is prohibiting participants who take a “break” or holiday from the drug.
  4. Closing the trial to new participants.

These changes obviously affect those who are in the trial, but they also restrict future access to ME patients.
Ampligen patients have met with the company and petitioned the Board of Hemispherx saying: “Hemispherx’s changes to the program are predatory and cruel, given the desperate need for treatment among this patient population.”
Meanwhile, Hemispherx announced this week that it was shipping Ampligen inventory to Europe for use in the Early Access Program in the EU.
Ampligen patients also believe these drastic changes will harm prospects for FDA approval of this first ME medication, pointing out  to the company the central role patients have played in pushing the FDA to recognize ME and approve Ampligen:
“Patients on Ampligen have been the force behind urging the FDA to approve it. We have led dramatic efforts to change FDA’s beliefs about the disease and Ampligen’s efficacy, including 700 testimonies during the advisory committee hearing, a 5,000 plus petition to the FDA, a patient hunger strike protesting FDA denial, a stakeholder and other important meetings at FDA, and Congressional and HHS outreach.”
The entire ME community has an interest in the successful pursuit of FDA approval for the first medicine for our disease. Approval of the first ME medication will lead to more clinical trials and investment by the larger pharmaceutical industry. Reducing the Ampligen trial is not a successful strategy for FDA approval.
Please join Ampligen patients in making sure Hemispherx puts ME patients first to prevent damage to participants’ health and future approval prospects.
Sign the petition to tell Hemispherx to reverse these draconian changes to the Ampligen clinical trial that will hurt the ME community.
 

Facebook
Twitter
WhatsApp
Email

2 thoughts on “Drastic changes to Ampligen clinical trial hurts ME patients – sign the petition to fight it”

  1. This type of issue requires civil disobedience targeting the pharma company. I would be surprised if pharma did anything after receiving a petition.

  2. I seriously do not understand this article.
    To the best of my knowledge, there is no current trial of Ampligen in the US. So how can there be any changes to it, if it doesn’t exist?

Comments are closed.

Latest News

#MEAction Scotland volunteers in Scottish Parliament

Volunteers from #MEAction Scotland and Long Covid Scotland talked to over 60 MSPs (Members of the Scottish Parliament) at an Information Stall in the Scottish Parliament from 5th-7th November. Ben Macpherson MSP for Edinburgh Northern and Leith sponsored the stall on behalf of  #MEAction Scotland as we aimed to make MSPs aware of the desperate

Read More »
hunter green rectangle image with fall leaves around the boarder. in the center the #meaction logo and the words, What we are thankful for

#MEAction Gives Thanks

We have come to the time of year, where we focus on what we are thankful for and what has made a difference in our lives. At #MEAction we will always be thankful for this amazing community, for you truly are OUT OF THIS WORLD! With this focus, #MEAction staff share what they are most

Read More »
Scroll to Top